Called xanthosteen 3510, the new addition to the company's portfolio of mangosteen ingredients is standardized to 3,500µmoleTE/g ORAC total, 10 percent alpha-mangostin by HPLC and 20 per cent polyphenols.
The company already offers two mangosteen peel ingredients - a peel powder standardized to not less than 1500 ORAC per gram and a tea cut - as well as freeze dried mangosteen fruit powder.
Mangosteen is a fruit native to southeast Asia which is relatively unknown in North America.
Stefan Wypyszyk, vice president of marketing for MB North America, said the benefit of the extract is that it permits a more manageable dose of antioxidants.
Wypsyzyk added that mangosteen is commonly used in soap products in Asia. Its antibacterial properties mean it is ideal for use in acne products.
It also tightens the skin, which, combined with the anti-oxidant properties, makes it ideal for anti-aging skin care products.
Four kilograms of dried peels are used to produce each kilogram of the extract.
He added that the extract, which costs around five times as much as the powder, is also more suitable for use in supplements and beverages.
Most of the pre-clinical work on mangosteen has centered on alpha- and beta-mangostin, xanthones that are responsible for its high ORAC (Oxygen Radical Absorbance Capacity) value.
Wypyszyk drew attention to a number of studies indicating the health benefits of these xanthones, including immunomodulatory action and their ability to induce apoptosis (cell death) in cancer cells.
Xanthosteen 3510 is being launched on a worldwide basis. It is manufactured in Germany by Finzelberg under a pharmaceutical manufacturing license for the newly implemented European Union Good Manufacturing Practices.
Finzelberg is also handling sales in Asia and Europe. The European launch is taking place this week at the pharmaceutical market CPhi in Madrid.
Wypyszyk added that use of the ingredient around the world depends on local regulations, but that there are no regulatory issues in the US.